| ²é¿´: 375 | »Ø¸´: 8 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
lw1966hhhÌú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[½»Á÷]
¡¶Insights The Cancer Market Outlook to 2009¡·
|
||
|
This report quantifies the patient potential in different cancer sub-markets and provides benchmarks for new cancer drug development and marketing strategies; identifying key areas of unmet need and profiling the market leading products of the future. The global cancer market is characterized by a mix of established gold standard therapies and new innovative products rapidly capturing market share. While a number of blockbuster therapies lose patent protection, heavy R&D investment has resulted in 400 potential new drugs currently progressing through clinical trials. Significant unmet needs and high incidence of disease continue to drive market growth, leaving a number of companies competing to improve treatment efficacy and drive market share. Use this report to quantify patient potential in cancer sub-markets, benchmark your portfolio against the eight leading companies in the sector and devise strategies to counter threats to your market position in the next five years. http://rapidshare.de/files/28238 ... Outlook_to_2009.pdf |
» ²ÂÄãϲ»¶
²Î±ÈÖÆ¼Á£¬×Ô¼º×öµÄPKÊý¾ÝÓëIF×ÊÁϱ¨µÀµÄÊý¾ÝÏà²îºÜ´ó
ÒѾÓÐ2È˻ظ´
ÆíÇóÖб¾×Ó
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ58È˻ظ´
ÄÔ¹£ÔõôÖÎÁÆ
ÒѾÓÐ3È˻ظ´
ÄÔ¹£ÔõôÖÎÁÆ
ÒѾÓÐ0È˻ظ´
¸÷λ´óÀУ¬H¿ÚÃæÉÏʲôʱºò»áÆÀ£¿£¿£¿
ÒѾÓÐ30È˻ظ´
ÉúÎï×éÖ¯ÖÐÓÐÄ¿±ê·ÖÎöÎרÊôÐÔÔõô×ö
ÒѾÓÐ0È˻ظ´
¹ØÓÚSCIÔÓÖ¾·¢±í¹ÒÃû
ÒѾÓÐ32È˻ظ´
2026Äêɽ¶«´óѧº£ÑóѧԺÉúÎïÓëÒ½Ò©²©Ê¿ÕÐÉú-Àîϼ¿ÎÌâ×é
ÒѾÓÐ0È˻ظ´
²©Ê¿Ñо¿ÉúÕÐÉú
ÒѾÓÐ0È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´

yangdongyu
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ¹ó±ö: 0.138
- ½ð±Ò: 475.5
- Ìû×Ó: 205
- ÔÚÏß: 5.5Сʱ
- ³æºÅ: 7828
- ×¢²á: 2003-04-22
- ÐÔ±ð: GG
- רҵ: ¿¹Ö×ÁöÒ©ÎïÒ©Àí
7Â¥2007-03-08 21:54:05














»Ø¸´´ËÂ¥